Nife-Par (Nifedipine)

Nifedipine blocks L‑type calcium channels in the smooth muscle of arteries. By preventing calcium entry, the muscle relaxes, causing vasodilation. This reduces peripheral vascular resistance, leading to a fall in systemic blood pressure and decreased cardiac workload.

The dosage of Nife-Par is individualized by the prescribing clinician based on the patient’s condition, response, and tolerance. Healthcare providers determine the appropriate strength, frequency, and duration, and patients should follow the prescription label exactly.

Safety data for nifedipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding must discuss use with their healthcare professional.

To request Nife-Par, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nifedipine belongs to the dihydropyridine calcium‑channel blocker class, which primarily causes arterial vasodilation. Compared with ACE inhibitors or beta‑blockers, it may produce a quicker reduction in blood pressure but can be associated with reflex tachycardia and peripheral edema. Choice depends on patient profile and comorbidities.

Nife-Par should be stored at ambient temperature, below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture, heat, and direct sunlight, and ensure they are out of reach of children.

Nife-Par is taken orally, usually with a full glass of water. It may be taken with or without food, but consistency with meals can help reduce gastrointestinal discomfort. Patients should swallow the tablet whole and not crush or chew it unless directed by a healthcare professional.

Serious adverse events include severe hypotension, myocardial infarction, atrioventricular block, and life‑threatening arrhythmias. Patients should seek immediate medical attention if they experience fainting, chest pain, rapid or irregular heartbeat, or signs of an allergic reaction such as swelling or difficulty breathing.

Nife-Par should not be used by individuals with known hypersensitivity to nifedipine or any other dihydropyridine calcium‑channel blockers. Caution is also advised for patients with severe aortic stenosis, unstable angina, or recent myocardial infarction, and it is contraindicated in those taking strong CYP3A4 inhibitors without medical supervision.